A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Inclusion Criteria: * Patients with RRMS according to 2017 revised McDonald criteria * Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment * Patient with a MRI performed within three months before the enrollment * Patient eligible to ozanimod according to SmPC Exclusion Criteria: * Patients with clinical forms of MS other than RRMS * Patients unable to participate for various reasons * Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective * Contraindications to ozanimod according to SmPC Other protocol-defined Inclusion/Exclusion Criteria apply.